Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GONAL-F RFF REDI-JECT vs A.P.L.
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GONAL-F (follitropin alfa) is a recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian follicles, stimulating follicular growth, maturation, and estrogen production.
A. P. L. (Chorionic Gonadotropin) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads to stimulate testosterone production in males and ovulation in females.
Ovulation induction in anovulatory women,Controlled ovarian hyperstimulation for assisted reproductive technologies (ART),Spermatogenesis induction in hypogonadotropic hypogonadism (with h CG)
Induction of ovulation in anovulatory infertile women,Treatment of hypogonadism and cryptorchidism in males,Off-label: Assisted reproductive technology (ART) protocols
Subcutaneous injection. Initial dose 75-225 IU once daily for 7-14 days, titrated based on ovarian response. Maximum daily dose 450 IU.
500-1000 mg every 4-6 hours, not to exceed 3000 mg/day in adults.
Terminal elimination half-life: approximately 24 hours; clinically, steady-state is achieved within 3-5 days of daily dosing.
Terminal elimination half-life: 2.5–3.5 hours (elimination phase); clinical context: requires repeated dosing for sustained effect.
Primarily metabolized in the liver via peptide hydrolysis, with renal excretion of metabolites.
Primarily via glucuronidation (60%) and sulfation (35%) in the liver, with a minor portion (5%) via CYP2E1 oxidation to the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is normally detoxified by glutathione.
Renal: approximately 70-80% of the dose; fecal: <20%
Renal: 10% unchanged; hepatic metabolism to inactive metabolites excreted in urine and feces (90% combined).
Approximately 30-40% bound to plasma proteins, primarily albumin.
80–90% bound to sex hormone-binding globulin (SHBG) and albumin.
Approximately 8-10 L/kg, indicating extensive distribution into extracellular fluid.
0.5–0.9 L/kg, indicating moderate tissue distribution (primarily gonads and liver).
Subcutaneous: approximately 70-80%.
IM: 100%; Subcutaneous: ~80% (relative to IM); Oral: <5% (not clinically used).
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min) or dialysis; use with caution.
No specific adjustment required for mild to moderate renal impairment. In severe renal impairment (Cr Cl < 10 m L/min), extend dosing interval to every 8 hours.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution.
Caution in severe hepatic impairment; consider dose reduction or extended interval. Avoid use in active liver disease.
Not indicated for use in pediatric patients. Safety and effectiveness not established.
Weight-based: 10-15 mg/kg every 4-6 hours, not to exceed 5 doses per day or 75 mg/kg/day.
Not indicated for use in geriatric patients. Safety and effectiveness not established.
No specific dose adjustment, but consider renal and hepatic function and avoid exceeding 3000 mg/day.
GONAL-F should only be used by physicians thoroughly familiar with infertility problems and their management. Use may lead to ovarian hyperstimulation syndrome (OHSS) and multiple gestations.
No black box warning.
Ovarian Hyperstimulation Syndrome (OHSS): risk of severe OHSS with pulmonary and vascular complications,Ovarian torsion and rupture,Multiple gestation and birth defects,Thromboembolic events,Ectopic pregnancy,Ovarian neoplasms,Respiratory distress syndrome in offspring
May cause fluid retention, ovarian hyperstimulation syndrome (OHSS) in females,Increased risk of thromboembolic events,Precocious puberty in males,Not for use in prepubertal children unless for cryptorchidism
Hypersensitivity to follitropin alfa or any excipient,High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Sex hormone-dependent tumors (e.g., ovarian, breast, uterine),Pregnancy,Ovarian cyst or enlargement of unknown origin
Hypersensitivity to chorionic gonadotropin or any component,Precocious puberty (in males),Prostatic carcinoma or other androgen-dependent neoplasms,Ovarian cyst or enlargement not due to polycystic ovary syndrome
No known food interactions. No dietary restrictions required. However, grapefruit juice may increase estrogen levels and should be avoided during treatment. Maintain adequate hydration.
No known food interactions. Avoid alcohol during treatment.
FDA Pregnancy Category X. Contraindicated in pregnancy. No fetal risk data in first trimester due to lack of exposure; however, follicular stimulation may induce ovarian hyperstimulation syndrome and multiple gestations. Second and third trimester: no indicated use; potential for harm based on animal studies.
A. P. L. (chorionic gonadotropin) is not expected to increase the risk of congenital anomalies when used in early pregnancy. However, use in the first trimester is generally avoided unless indicated for specific conditions. Data are limited; no increased fetal risk reported in inadvertent exposures. Second and third trimester use is not associated with teratogenicity but may increase risk of multiple gestation (if used for ovulation induction).
Not recommended during breastfeeding. Excretion in human milk unknown; M/P ratio not determined. May suppress lactation due to hormonal effects.
Chorionic gonadotropin is not detected in breast milk following maternal administration. M/P ratio not established. Considered compatible with breastfeeding; no adverse effects on infant reported. Use with caution if high doses are administered.
No dose adjustment; drug is contraindicated in pregnancy and should be discontinued if pregnancy occurs. No pharmacokinetic changes studied in pregnancy due to contraindication.
No pharmacokinetic studies in pregnancy. Dose adjustments are not typically required during pregnancy for standard indications. For ovulation induction, dosing is based on follicular development. In first trimester for luteal support, standard doses are used. No evidence of altered clearance or need for dose changes due to pregnancy.
GONAL-F RFF REDI-JECT contains recombinant human follicle-stimulating hormone (follitropin alfa). It is used for ovulation induction and controlled ovarian hyperstimulation. Administer subcutaneously, rotating injection sites. Monitor ovarian response via ultrasound and estradiol levels to avoid ovarian hyperstimulation syndrome (OHSS). Dose adjustments based on patient response; individualize therapy. Can be used in combination with Gn RH agonists or antagonists.
A. P. L. (chorionic gonadotropin) is used to trigger ovulation in assisted reproductive technology. Administer when follicles are mature (≥18 mm). Risk of ovarian hyperstimulation syndrome (OHSS) increases with higher doses. Monitor for abdominal pain, distension, and weight gain. Use caution in patients with prior thromboembolism.
Rotate injection sites (abdomen, thigh, upper arm) to reduce lipodystrophy.,Do not shake the Redi-Ject device; store in refrigerator (2-8°C) before first use, then at room temperature for up to 28 days.,Report severe pelvic pain, nausea, or rapid weight gain (possible OHSS).,Avoid alcohol and grapefruit juice as they may affect hormone levels.
This medication is given as an injection exactly as prescribed to trigger ovulation.,A single dose is usually sufficient; follow your doctor's timing instructions closely.,Common side effects include headache, fatigue, and injection site reactions.,Seek immediate medical help if you experience severe pelvic pain, nausea, vomiting, or sudden weight gain (signs of OHSS).,Report symptoms of blood clots: leg pain, chest pain, or shortness of breath.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GONAL-F RFF REDI-JECT vs A.P.L., answered by our medical review team.
GONAL-F RFF REDI-JECT is a Gonadotropin that works by GONAL-F (follitropin alfa) is a recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian follicles, stimulating follicular growth, maturation, and estrogen production.. A.P.L. is a Gonadotropin that works by A. P. L. (Chorionic Gonadotropin) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads to stimulate testosterone production in males and ovulation in females.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GONAL-F RFF REDI-JECT and A.P.L. depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GONAL-F RFF REDI-JECT is: Subcutaneous injection. Initial dose 75-225 IU once daily for 7-14 days, titrated based on ovarian response. Maximum daily dose 450 IU.. The standard adult dose of A.P.L. is: 500-1000 mg every 4-6 hours, not to exceed 3000 mg/day in adults.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GONAL-F RFF REDI-JECT and A.P.L. in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GONAL-F RFF REDI-JECT is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy. No fetal risk data in first trimester due to lack of exposure; however, follicular stimulation may induce ovarian hyperstimu. A.P.L. is classified as Category C. A.P.L. (chorionic gonadotropin) is not expected to increase the risk of congenital anomalies when used in early pregnancy. However, use in the first trimester is generally avoided . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.